Eli Lilly and Company has announced a significant investment of $6.5 billion to establish a new active pharmaceutical ingredient (API) manufacturing facility in Houston, Texas. This...
A new study has unveiled promising results for a weight-loss pill that could significantly increase access to obesity treatment. The medication, known as orforglipron, has been...
Eli Lilly has announced the results of its third phase 3 trial for the oral weight-loss medication orforglipron, paving the way for regulatory submissions worldwide. In...
